Celgene obtained data protection (innovative drug status) for THALOMID® brand drug (thalidomide). In a decision released February 6, 2012, the Federal Court granted Celgene's application for judicial review against the Minister's decision to refuse data protection to Celgene in respect of THALOMID® brand drug (thalidomide).